Sponsor: Childrens Oncology Group - COG
Sponsor Study ID: ANBL2131
Study Title: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
CTO #: 104176
NCT Number: NCT06172296
Phase: III
Protocol Type: Treatment
Age Group: Children
Disease Sites: Kidney
Study Objectives: To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.